Medication Guide

In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.

Which Patients Are Suitable for Taking Ixazomib?

Ixazomib is indicated for the treatment of multiple myeloma, a type of bone marrow cancer. Its mechanism of action involves inhibiting a protein that drives the growth and prolifer···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：132
What are the indications of Ixazomib?

Ixazomib is a second-generation proteasome inhibitor that has emerged as a pivotal therapeutic option for the treatment of multiple myeloma.What are the indications of Ixazomib?Ixa···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：133
How Much Does One Box of Ixazomib Cost?

Ixazomib is a targeted, reversible proteasome inhibitor that has been approved for use in combination with lenalidomide and dexamethasone for the treatment of relapsed multiple mye···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：157
Latest Price Information on Lucius Ixazomib (2026)

Ixazomib is part of an all-oral treatment regimen. When used in combination with lenalidomide and dexamethasone, it provides a convenient treatment option for patients with multipl···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：170
The U.S. FDA Grants Priority Review Status to Takeda’s Ixazomib for the Treatment of Relapsed/Refrac

On September 9, 2015, Cambridge, Massachusetts, USA, and Osaka, Japan, announced that the U.S. Food and Drug Administration (FDA) had granted priority review status to the New Drug···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：131
The U.S. Food and Drug Administration (FDA) has approved ixazomib for the treatment of multiple myel

The U.S. Food and Drug Administration (FDA) approved ixazomib today for use in combination with two other therapies to treat patients with multiple myeloma who have received at lea···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：137
Important Precautions for Ivosidenib Use

Ivosidenib is available only with a doctor's prescription.Important Precautions for Ivosidenib UseIf you experience any changes in heart rhythm, contact your doctor immediately···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：207
Sotorasib(Lumakras)

‌KRAS G12C mutation in non-small cell lung cancer and colorectal cancer‌【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：65
Larotrectinib(Vitrakvi)

Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：61
Lorlatinib(Lorbrena)

Non-small cell lung cancer【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：106
Gilteritinib(Xospata)

Gilteritinib is suitable for Leukemia.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：69
Capmatinib(Tabrecta)

Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：154

home page previous 37 37/98 next last page

News

The U.S. FDA approved the combination of Pembrolizumab and Enfortumab vedotin-ejfv for the treatment
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】

Recommended：4512025-17-12
Lucius Pharmaceuticals Laos launched lorlatinib, a third-generation targeted drug for lung cancer
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】

Recommended：6382024-09-07
Imfinzi received approval in the U.S., becoming the first and only immuno-combination therapy for BC
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】

Recommended：952026-01-06
FDA approves niraparib in combination with abiraterone acetate plus prednisone for metastatic castra
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】

Recommended：4162025-15-12
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】

Recommended：4402025-10-12
FDA Approves Lisocabtagene Maraleucel for the Treatment of Relapsed or Refractory Marginal Zone Lymp
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】

Recommended：4252025-08-12
The FDA has approved pirtobrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】

Recommended：4802025-04-12
Combination therapy of tucatinib and T-DM1 significantly improves progression-free survival in patie
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】

Recommended：3882025-01-12

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More

Hospital Departments

Medication Guide

Related Articles

Which Patients Are Suitable for Taking Ixazomib?

What are the indications of Ixazomib?

How Much Does One Box of Ixazomib Cost?

Latest Price Information on Lucius Ixazomib (2026)

The U.S. FDA Grants Priority Review Status to Takeda’s Ixazomib for the Treatment of Relapsed/Refrac

The U.S. Food and Drug Administration (FDA) has approved ixazomib for the treatment of multiple myel

Important Precautions for Ivosidenib Use

Sotorasib(Lumakras)

Larotrectinib(Vitrakvi)

Lorlatinib(Lorbrena)

Gilteritinib(Xospata)

Capmatinib(Tabrecta)

News

The U.S. FDA approved the combination of Pembrolizumab and Enfortumab vedotin-ejfv for the treatment

Lucius Pharmaceuticals Laos launched lorlatinib, a third-generation targeted drug for lung cancer

Imfinzi received approval in the U.S., becoming the first and only immuno-combination therapy for BC

FDA approves niraparib in combination with abiraterone acetate plus prednisone for metastatic castra

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia

FDA Approves Lisocabtagene Maraleucel for the Treatment of Relapsed or Refractory Marginal Zone Lymp

The FDA has approved pirtobrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small

Combination therapy of tucatinib and T-DM1 significantly improves progression-free survival in patie

Sotorasib

Adagrasib

Larotrectinib

Lorlatinib

Gilteritinib

Capmatinib

Selinexor

Ivosidenib

Mobocertinib

Olaparib

Product

Product

Contact US